BAVA Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, November 11, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NamePaul Chaplin
2.Reason for the notification
a)Position/status



 
President and Chief Executive Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.00123,645
d)Aggregated information
  • Aggregated volume
  • Price
 



123,645

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Juuel
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Financial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0056,210
d)Aggregated information
  • Aggregated volume
  • Price
 



56,210

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameHenrik Birk
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0052,617
d)Aggregated information
  • Aggregated volume
  • Price
 



52,617

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameTommi Kainu
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Business Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0051,157
d)Aggregated information
  • Aggregated volume
  • Price
 



51,157

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameJean-Christophe May
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Commercial Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0047,970
d)Aggregated information
  • Aggregated volume
  • Price
 



47,970

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameLaurence De Moerlooze
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Medical Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0047,965
d)Aggregated information
  • Aggregated volume
  • Price
 



47,965

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameAnu Helena Kerns
2.Reason for the notification
a)Position/status



 
Executive Vice President People & Organization of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.0036,476
d)Aggregated information
  • Aggregated volume
  • Price
 



36,476

DKK 0.00
e)Date of the transaction2020-11-11
f)Place of the transactionOutside a trading venue

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit .

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 48 / 2020

Attachment

EN
11/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley

Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 5. november 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 30. oktober 2025 besidder 4,92% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre ...

 PRESS RELEASE

Bavarian Nordic Announces Major Shareholder Notification from Morgan S...

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley COPENHAGEN, Denmark, November 5, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.92% of the shares and voting rights in Bavarian Nordic A/S as of October 30, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to e...

 PRESS RELEASE

Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley

Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 4. november 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 29. oktober 2025 besidder 5,12% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre ...

 PRESS RELEASE

Bavarian Nordic Announces Major Shareholder Notification from Morgan S...

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley COPENHAGEN, Denmark, November 4, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.12% of the shares and voting rights in Bavarian Nordic A/S as of October 29, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to e...

 PRESS RELEASE

Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley

Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 31. oktober 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 27. oktober 2025 besidder 4.99% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch